MICHELL CADIZ: Open Payments
NPI 1194161554 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,020 in 106 payments from 27 companies in 2025. Trend: 2023 $6,378 · 2024 $2,302 · 2025 $4,020
Food & beverage: $2,550Consulting: $1,470
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 19 | $1,012 |
| Janssen Pharmaceuticals, Inc | 1 | $915 |
| Novartis Pharmaceuticals Corporation | 19 | $368 |
| GENZYME CORPORATION | 9 | $288 |
| AstraZeneca Pharmaceuticals LP | 11 | $239 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $183 |
| PFIZER INC. | 7 | $166 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| SOBI, INC | 3 | $104 |
| Rigel Pharmaceuticals, Inc. | 3 | $80 |
Products named: DARZALEX, Fabhalta, CALQUENCE, TECVAYLI, SARCLISA, RYBREVANT, AYVAKIT, TALVEY.
Industry payments across CA — which companies pay providers there.
